FATE-NK100 Shows Signs of Tumor Reduction in First Ovarian Cancer Patients in Phase 1 Trial
News
FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so ... Read more